BMEA (Biomea Fusion Inc) Net Profit

Official company branding of Biomea Fusion Inc (BMEA)

This price chart for BMEA reflects the asset's dynamics, where the current indicator stands at -0.03. Biomea Fusion, Inc. (BMEA) relies on intensive scientific research, preparing revolutionary data on beta-cell regeneration for diabetes. Biomea Fusion, Inc. (BMEA) is creating a cutting-edge therapeutic environment for oncology and endocrine disorders using covalent inhibitors, aiming to eliminate the root causes of metabolic dysfunctions within the framework of future medicine.

BMEA (Biomea Fusion, Inc.) Company Net Income history from 07/04/2022 to 10/30/2026

Comprehensive metric breakdowns and analytics for Biomea Fusion (BMEA)

- price and consensus price forecast:
Stock Quotes Biomea Fusion Corp|BMEA - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Biomea Fusion Corp|BMEA - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Biomea Fusion|BMEA - Company Book Value|Market Cap to Net Assets Ratio biomeafusion.com|BMEA - Company Total Assets
- debt and solvency information:
Debt to Capital Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Biomea Fusion Inc|BMEA - Company Aggregate Debts|Debts to Book Capitalization Biomea Fusion Corp|BMEA - Company Long-Term Debts|Company Short-Term Debt Biomea Fusion|Immediate Liquidity biomeafusion.com
- net income and valuation multiples indicators:
BMEA - Company Net Income
Fundamental valuation:Biomea Fusion, Inc.
Signature product of biomeafusion.com

Biomea Fusion, Inc. (BMEA) is developing the high-tech metabolic therapy sector. Effective research outsourcing allows for cost optimization, which directly impacts the company's net cash flow. This indicator accumulates daily net profit, transforming static reports into a dynamic tool for monitoring profitability. Line stability confirms operational resilience, while volatility signals structural changes. Analyzing these fluctuations helps investors determine optimal entry points.

Direct competitors

Net Income Ascendis|MDGL (Madrigal Pharmaceuticals) - Net Profit|Net Profit corcept.com|Net Income RYTM (Rhythm Pharmaceuticals, Inc.)|AKRO (Akero Therapeutics, Inc.) - Final Profit|Company Net Income Metsera Corp MTSR|MLTX - Net Income|Crinetics Pharmaceuticals - Net Profit|Company Net Income newamsterdampharma.com|SLNO (Soleno Therapeutics, Inc.) - Net Income|FOLD: Profit After Payment of Taxes|ETNB (89bio Corp) - Net Profit|Net Profit Agios Corp|Net Profit GPCR|Company Net Income MDXG (mimedx.com)|Company Net Income Rezolute RZLT|Lexicon Pharmaceuticals Inc (LXRX) - Company Net Income|MBX - Company Net Income|ALT: Company Net Income|AARD: Net Profit|SGMT - Net Financial Result|Company Net Income BioAge|Quince (QNCX) - Net Financial Result|Company Net Income Fractyl (GUTS)|Net Income vtvtherapeutics.com VTVT|Net Profit ATPC (Agape ATP)|Pluristem Therapeutics - Company Net Income|Synlogic Corp - Net Profit|Net Financial Result Lipocine Inc LPCN|matinasbiopharma.com (MTNB) - Company Net Income|Company Net Income Spruce Biosciences Inc. (SPRB)|Company Net Income Galecto, Inc.|Net Income carmellrx.com (CTCX)|Net Profit LUMO|ONVO - Company Net Income|Net Profit RDUS (Radius Health)